Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773931 | 1.00 | PTPN1 (0.54) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL6508024 | 1.00 | PTPN1 (0.54) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL864823 | 1.00 | PTPN1 (0.54) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL29502321 | 1.00 | PTPN1 (0.54) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL30254985 | 1.00 | PTPN1 (0.54) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL546157 | 0.95 | ESR2 (0.56) | PTPN1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL2722678 | 0.89 | PTPN1 (0.53) | PTPN1HDAC8 | |
| SCHEMBL30592013 | 0.88 | PTPN1 (0.69) | PTPN1ESR2HDAC8 | |
| SCHEMBL29369360 | 0.88 | PTPN1 (0.69) | PTPN1ESR2HDAC8 | |
| SCHEMBL17486413 | 0.88 | PTPN1 (0.69) | PTPN1ESR2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3601258-B1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3601258-B1 | SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-110461829-B | Substituted isoquinoline derivatives as immunomodulators | 百时美施贵宝公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11046675-B2 | Substituted isoquionline derivatives as immunomudulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-29 | — | — | US | disclosed |
| CN-111840290-B | Application of isoquinoline compounds in killing or preventing ectoparasites of aquatic animals | 浙江省淡水水产研究所 | 2021-05-07 | — | — | CN | disclosed |
| EP-0923734-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | Trega Biosciences, Inc. (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1999028314-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-06-10 | — | — | WO | disclosed |
| US-5840500-A | OPIOD RECEPTORS AS ANALGESICS AND CENTRALLY ACTING PAIN KILLERS | TREGA BIOSCIENCES, INC. (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0865439-A4 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS INC (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0865439-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-23 | — | — | EP | disclosed |
| WO-1998002741-A9 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | — | 1998-05-22 | — | — | WO | disclosed |
| WO-1998002741-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-01-22 | — | — | WO | disclosed |
| EP-0788511-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996040672-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996011210-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046675-B2 | Substituted isoquionline derivatives as immunomudulators | CD74, HLA-DRB1, ICOS | PTPN1 205/4885ESR2 2751/4885OPRM1 1347/4885 |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PTPN1 358/4885ESR2 2271/4885OPRM1 4472/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PTPN1 358/4885ESR2 2271/4885OPRM1 4472/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PTPN1 358/4885ESR2 2271/4885OPRM1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.